+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia-Pacific Hyperphosphatemia Drugs Market 2019-2027

  • ID: 4791807
  • Report
  • Region: Asia Pacific
  • 73 pages
  • Triton Market Research
1 of 3

FEATURED COMPANIES

  • Amag Pharmaceuticals
  • Bruno Farmaceutici S.P.A.
  • Fermenta Biotech, Ltd.
  • Johnson and Johnson
  • Royal Dsm N.V.
  • Shire
  • MORE
Market Outlook

The This research report states that the Asia-Pacific hyperphosphatemia drugs market is expected to grow in terms of revenue with a CAGR of 17.86% during the forecast period 2019 to 2027.

The countries of India, China, Japan, South Korea, Australia & New Zealand, ASEAN countries and countries in rest of APAC together constitute the market for hyperphosphatemia drugs in the Asia-Pacific region.

The growth of Asia-Pacific hyperphosphatemia drugs market can majorly be attributed to the growing aging populace, increase in the cases of osteoporosis and the changing dietary habits of people. Amongst these, the high prevalence of osteoporosis is the major driver for the hyperphosphatemia drugs market in this region. Osteoporosis is significantly undertreated and underdiagnosed in this region, even in the high-risk patients who have experienced previous fractures. In Asia-Pacific’s most populated countries such as India and China, hip fractures are frequently treated conventionally at their house as an alternative to surgical treatment in hospitals.

Whereas, the changing dietary habits of people have led to the hyperphosphatemia drug market growth in Australia. The increased phosphate levels in the body give rise to hyperphosphatemia. High phosphate-containing foods are meat, dairy items, fast food, soft drinks, nuts, seeds, chocolates and processed food. The consumption of these food items increases the phosphorous level in the body, eventually leading to diseases such as hyperphosphatemia. Thus, the changing dietary habits and a shift from functional foods to processed foods are mainly responsible for causing hyperphosphatemia in the region.

Competitive Outlook

Top companies that have been studied in the market are Shire, Zeria Pharmaceutical, Sanofi, Royal DSM N.V., Keryx Biopharmaceuticals, Inc., Sun Pharmaceutical Industries, Ltd., Bruno Farmaceutici S.p.A., Fermenta Biotech, Ltd., Roche Diagnostics Corporation, Cipla, Bio-Tech Pharmacal, Fresenius Medical Care, Johnson and Johnson, Pfizer, Inc., AMAG Pharmaceuticals and Ultragenyx Pharmaceutical, Inc.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amag Pharmaceuticals
  • Bruno Farmaceutici S.P.A.
  • Fermenta Biotech, Ltd.
  • Johnson and Johnson
  • Royal Dsm N.V.
  • Shire
  • MORE
1. Asia-Pacific Hyperphosphatemia Drugs Market - Summary

2. Industry Outlook
2.1. Market Definition
2.2. Porter’s Five Force Model
2.2.1. Threat of New Entrants
2.2.2. Bargaining Power of Buyers
2.2.3. Bargaining Power of Suppliers
2.2.4. Threat of Substitute Product
2.2.5. Intensity of Competitive Rivalry
2.3. Vendor Scorecard
2.4. Key Buying Outlook
2.5. Key Insights
2.6. Key Market Trends
2.7. Guidelines Related to the Phosphate Binders
2.8. Market Drivers
2.8.1. Chronic Disorders are Increasing Rapidly
2.8.2. Increase in Public Cognizance
2.8.3. Increase in Geriatric Population
2.9. Market Restraints
2.9.1. Side-Effects Related to the Usage of Hyperphosphatemia Drugs
2.9.2. Strict Food and Drug Administration (Fda) Regulations
2.10. Market Opportunities
2.10.1. Rise in the Aging Population
2.11. Market Challenges
2.11.1. Alternative Dialysis Techniques
2.11.2. Accessibility of Drugs is Limited
2.11.3. Non-Adherence to Treatment Regimes

3. Hyperphosphatemia Drugs Market Outlook - By Dosages
3.1. Solid
3.1.1. Tablet
3.1.2. Powder
3.2. Liquid
3.2.1. Solution

4. Hyperphosphatemia Drugs Market Outlook - By Formulation
4.1.1. Calcium-Based Phosphate Binders
4.1.2. Aluminum-Based Phosphate Binders
4.1.3. Magnesium-Based Phosphate Binders
4.1.4. Iron-Based Phosphate Binders
4.1.5. Other Phosphate Binders

5. Hyperphosphatemia Drugs Market - Regional Outlook
5.1. Asia-Pacific
5.1.1. Country Analysis
5.1.1.1. India
5.1.1.2. China
5.1.1.3. Japan
5.1.1.4. South Korea
5.1.1.5. Asean Countries
5.1.1.6. Australia & New Zealand
5.1.1.7. Rest of Apac

6. Competitive Landscape
6.1. Johnson and Johnson
6.2. Zeria Pharmaceutical
6.3. Amag Pharmaceuticals
6.4. Sanofi
6.5. Bruno Farmaceutici S.P.A.
6.6. Roche Diagnostics Corporation
6.7. Royal Dsm N.V.
6.8. Shire
6.9. Cipla
6.10. Ultragenyx Pharmaceutical, Inc.
6.11. Fermenta Biotech, Ltd.
6.12. Biotech Pharmacal
6.13. Sun Pharmaceutical Industries, Ltd.
6.14. Keryx Biopharmaceuticals, Inc.
6.15. Fresenius Medical Care
6.16. Pfizer, Inc.

7. Methodology & Scope
7.1. Research Scope
7.2. Sources of Data
7.3. Research Methodology

Tables List
Table 1 Asia-Pacific Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Table 2 Phosphorous Levels in Select Foods
Table 3 Asia-Pacific Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 4 Diagnosis and Clinical Indicators of Chronic Kidney Disease
Table 5 Asia-Pacific Hyperphosphatemia Drugs Market Country Analysis 2019-2027 ($ Million)
Table 6 Per Capita Consumption of Dairy Products in Australia

Figures List
Figure 1 Porter’s Five Force Model of Hyperphosphatemia Drugs Market
Figure 2 Iron-Based Hyperphosphatemia Drug Approval Status 2014-2017
Figure 3 Rate of Adherence to Phosphate Binders
Figure 4 Asia-Pacific Hyperphosphatemia Drugs Market in Calcium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 5 Asia-Pacific Hyperphosphatemia Drugs Market in Aluminum-Based Phosphate Binders 2019-2027 ($ Million)
Figure 6 Asia-Pacific Hyperphosphatemia Drugs Market in Magnesium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 7 Asia-Pacific Hyperphosphatemia Drugs Market in Iron-Based Phosphate Binders 2019-2027 ($ Million)
Figure 8 Asia-Pacific Hyperphosphatemia Drugs Market in Other Phosphate Binders 2019-2027 ($ Million)
Figure 9 Asia-Pacific Hyperphosphatemia Drugs Market Share 2018 & 2027 (%)
Figure 10 Asia-Pacific Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 11 Agewise Distribution of Elderly Population in India
Figure 12 India Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 13 China Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 14 Japan Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 15 Number of Fractures Due to Osteoporosis and Osteopenia
Figure 16 South Korea Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 17 Asean Countrieshyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 18 Australia & New Zealand Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 19 Roapac Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Johnson and Johnson
  • Zeria Pharmaceutical
  • Amag Pharmaceuticals
  • Sanofi
  • Bruno Farmaceutici S.P.A.
  • Roche Diagnostics Corporation
  • Royal Dsm N.V.
  • Shire
  • Cipla
  • Ultragenyx Pharmaceutical, Inc.
  • Fermenta Biotech, Ltd.
  • Biotech Pharmacal
  • Sun Pharmaceutical Industries, Ltd.
  • Keryx Biopharmaceuticals, Inc.
  • Fresenius Medical Care
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll